Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Feb 28 2023

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release detailing two final approvals from the USFDA for its medications. The first approval is for Apixaban Tablets, which are used to reduce the risk of stroke and blood clots. The second approval is for Olmesartan Medoxomil and Hydrochlorothiazide Tablets, used for treating high blood pressure. Both drugs will be manufactured at Zydus's facilities in India.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 28, 2023, titled "(1)Zydus receives final approval from the USFDA for Apixaban Tablets, 2.5 mg and 5 mg and(2) Zydus receives final approval from the USFDA for Olmesartan Medoxomil andHydrochlorothiazide Tablets".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases